13F-HR filed by Sarissa Capital Management LP
Sarissa Capital Management LP filed this 13F-HR for the quarter ended 2025-09-30, filed 2025-11-14, with 8 holding rows worth $180,391,813.
- Accession
- 0000899140-25-001320
- Filer
- CIK 1577524
- Filed
- 2025-11-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q3 2025
A holdings report, 8 entries on the cover page, a total value of $180,391,813 stated on the cover page (in dollars after the unit check, H1), rows summing to $180,391,813 with VALUE read as dollars as filed, 13F file number 028-15935. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| INNOVIVA INC | 45781M101 | COM | 2,816,022 | $51,392,402 | dollars as filed | |
| NEUROCRINE BIOSCIENCES INC | 64125C109 | COM | 303,151 | $42,556,337 | dollars as filed | |
| CYTOKINETICS INC | 23282W605 | COM NEW | 588,357 | $32,336,101 | dollars as filed | |
| IRONWOOD PHARMACEUTICALS INC | 46333X108 | COMMON STOCK | 15,919,435 | $20,854,460 | dollars as filed | |
| AMARIN CORP PLC | 023111404 | SPONSORED ADR | 1,242,527 | $20,352,592 | dollars as filed | |
| LANTHEUS HLDGS INC | 516544103 | COM | 181,450 | $9,306,571 | dollars as filed | |
| REGENERON PHARMACEUTICALS COM | 75886F107 | Stock | 4,190 | $2,355,911 | dollars as filed | |
| VOR BIOPHARMA INC | 929033207 | COMMON STOCK | 25,399 | $1,237,439 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000899140-25-001320 | this filing | 2025-11-14 | acceptance time not in the bulk data set |